Dana Investment Advisors Inc. Has $1.61 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Dana Investment Advisors Inc. trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 10.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,338 shares of the insurance provider’s stock after selling 775 shares during the period. Dana Investment Advisors Inc.’s holdings in Humana were worth $1,608,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HUM. Transcend Capital Advisors LLC lifted its stake in Humana by 399.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock valued at $924,000 after purchasing an additional 2,914 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the last quarter. Retirement Systems of Alabama lifted its stake in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the last quarter. PDT Partners LLC lifted its stake in Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after purchasing an additional 2,660 shares during the last quarter. Finally, Secure Asset Management LLC acquired a new stake in Humana in the 4th quarter valued at about $244,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.32% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $259.86 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $31.35 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 2.05 and a beta of 0.57. The firm’s 50 day simple moving average is $271.80 and its 200 day simple moving average is $283.63. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.36%. Humana’s dividend payout ratio is 35.58%.

Analysts Set New Price Targets

HUM has been the topic of several research analyst reports. Piper Sandler increased their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Barclays increased their price target on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.